Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 30, 2026.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. has 141.14M shares outstanding.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. maintains a current ratio of 5.90, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 211.07, indicating elevated leverage, while an interest coverage ratio of -2.17 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Arrowhead Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -64.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -18.32, reflecting losses generated across the asset base. The company generates approximately 824,203.90 in revenue per employee across its workforce of 711.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Arrowhead Pharmaceuticals, Inc. recorded 17.55M in income tax expense. The company reported a pretax loss of -220.64M and -280.05M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Arrowhead Pharmaceuticals, Inc. generated 586.01M in revenue and converted that into -280.05M in net income, yielding earnings per share of -1.69. EBITDA reached -175.62M, while operating income came in at -198.20M.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. holds 1.40B in cash and equivalents against 861.03M in total debt, resulting in a net debt position of 739.09M. Total book value stands at 407.48M, with working capital of 1.21B providing operational flexibility.

Arrowhead Pharmaceuticals, Inc. produced -51.69M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -14.05M in capital expenditures, free cash flow totaled -65.74M - equivalent to -0.47 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -33.82 and net profit margin of -47.79 provide insight into operational efficiency.

Arrowhead Pharmaceuticals, Inc.'s most recent stock split took place on November 17, 2011 with a 10:1 split ratio.